Melatonina Polfarmex

Melatonin, the active ingredient in Melatonina Polfarmex, is a melatonin receptor agonist presented as an oral formulation for oral use. It is used to help regulate the sleep‑wake cycle and is indicated for individuals experiencing difficulty falling or staying asleep, including primary insomnia and circadian rhythm sleep‑wake disorders.

GNH USA supplies Melatonina Polfarmex as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, adhering to stringent quality standards and providing regulatory documentation for cross‑border distribution.

Melatonin acts on the melatonin receptor pathway to address sleep‑related disorders. - Insomnia: assists in reducing sleep onset latency and improving total sleep time. - Sleep‑wake rhythm disorders: helps synchronize the circadian clock to a more regular pattern. - Jet lag: supports faster adjustment of the internal clock after rapid time‑zone travel.

Melatonin may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Drowsiness or daytime sleepiness - Headache - Dizziness - Nausea - Vivid dreams

Serious or Rare Side Effects: - Allergic skin reactions such as rash or urticaria - Severe hypersensitivity including anaphylaxis - Mood changes such as depression or agitation - Hormonal disturbances affecting puberty in children (rare)

Melatonin should be used with caution in specific populations and clinical situations. - Use in children: limit to short‑term under medical supervision. - Pregnancy and lactation: avoid unless benefits outweigh potential risks. - Concomitant CNS depressants: monitor for additive sedation. - Underlying psychiatric conditions: assess risk of mood alterations. - Store at ambient temperature below 25°C: keep in original container, protect from moisture and light.

Melatonin can interact with several medication classes, requiring attention to potential additive effects.

Major Interactions (Avoid): - Anticoagulants (e.g., warfarin): may increase bleeding risk. - Immunosuppressants (e.g., cyclosporine): potential reduction in efficacy.

Moderate Interactions (Monitor Closely): - CNS depressants (benzodiazepines, alcohol): enhanced sedative effect. - Antidiabetic agents: possible alteration of glucose control. - Hormonal contraceptives: may reduce contraceptive effectiveness. - Fluoroquinolone antibiotics: may increase risk of QT prolongation.